Core Viewpoint - Revival Gold Inc. has announced a strategic placement with EMR Capital Management Limited, which will result in a significant cash injection of US$10 million to support the company's gold production initiatives [1][3]. Group 1: EMR Strategic Placement - EMR will purchase 28,506,250 common shares at a price of C$0.48 per share, totaling gross proceeds of US$10 million (C$13.68 million) [1]. - EMR's pro-forma interest in Revival Gold is expected to be approximately 10.86% upon closing, assuming full subscription of the Concurrent Offering [2]. - EMR will receive customary anti-dilution rights and the right to nominate a director to the Board of Directors of Revival Gold [2]. Group 2: Concurrent Offering - Revival Gold plans to complete a non-brokered private placement of up to C$10.32 million by issuing up to 21,493,750 common shares at the same price of C$0.48 per share [4]. - The proceeds from both the EMR Strategic Placement and the Concurrent Offering will be used for the exploration and development of the Mercur and Beartrack-Arnett projects, as well as for general working capital [6]. Group 3: Regulatory and Closing Conditions - The offerings are subject to customary closing conditions, including necessary regulatory approvals, with expected closing around July 29, 2025 [8]. - Common shares issued under the Concurrent Offering will be offered to purchasers in Canada and may also be issued to purchasers outside Canada, including the United States, under applicable regulatory requirements [5]. Group 4: Company Overview - Revival Gold is one of the largest pure gold mine developers in the United States, focusing on the Mercur Gold Project in Utah and the Beartrack-Arnett Gold Project in Idaho [13].

Core Points - Mullen Group Ltd. has successfully closed a private placement of approximately CAD$400 million in senior secured notes due July 10, 2037 [1][2] - The notes consist of US$50 million with a yield of 6.91% per annum and CAD$325 million with a yield of 6.04% per annum, guaranteed by subsidiaries and secured by a first-ranking charge over the corporation's assets [2][3] - The net proceeds from the offering will be used to prepay existing private placement debt maturing in October 2026 and for general corporate purposes [2] Company Overview - Mullen Group is a public company with a significant portfolio in the transportation and logistics industries, providing a wide range of services including less-than-truckload, customs brokerage, and specialized hauling [5] - The company operates a network of independently operated businesses and offers specialized services related to energy, mining, forestry, and construction in western Canada [5] - Mullen Group is listed on the Toronto Stock Exchange under the symbol "MTL" [6]

Core Viewpoint - SeaStar Medical Holding Corporation has announced a definitive agreement for the issuance and sale of 5,242,464 shares of common stock at a price of $0.763 per share, along with unregistered warrants to purchase an equal number of shares at an exercise price of $0.638, aiming to raise approximately $4 million for general corporate purposes [1][2]. Group 1: Offering Details - The offering includes a registered direct offering priced at-the-market under Nasdaq rules and a concurrent private placement for unregistered warrants [1][2]. - The gross proceeds from the offering are expected to be around $4 million, with net proceeds intended for general corporate purposes, including working capital and capital expenditures [2]. Group 2: Regulatory and Compliance Information - The shares are being offered under a shelf registration statement previously filed with the SEC, which became effective on December 22, 2023 [3]. - The unregistered warrants are not registered under the Securities Act and cannot be sold in the U.S. without an effective registration statement or applicable exemption [4]. Group 3: Company Overview - SeaStar Medical is focused on transforming treatments for critically ill patients facing organ failure, with its first product, QUELIMMUNE, approved by the FDA in 2024 for life-threatening acute kidney injury in pediatric patients [6]. - The company’s Selective Cytopheretic Device therapy has received Breakthrough Device Designation for six therapeutic indications, indicating a potential for expedited approval processes [6]. - SeaStar is conducting a pivotal trial of its SCD therapy in adult patients with acute kidney injury, a condition affecting over 200,000 adults in the U.S. annually [6].

Core Viewpoint - Bessor Minerals Inc. has successfully completed a non-brokered private placement, raising $100,000 through the issuance of 5,000,000 common shares at a price of $0.02 per share [1][2] Group 1: Private Placement Details - The private placement was announced on May 16, 2025, and completed on July 9, 2025, with all securities subject to a four-month hold period [1][2] - The net proceeds from the private placement will be allocated for potential exploration of Bessor's properties, future acquisitions, and general working capital [2] - The private placement utilized available prospectus exemptions under securities laws, including the accredited investor exemption [2] Group 2: Regulatory Compliance - The issuance of 350,000 common shares was made to Zygmunt Hancyk, a director of Bessor, which was compliant with MI 61-101 regulations [3] - Bessor relied on specific exemptions from formal valuation and minority approval requirements due to its listing status on the TSX Venture Exchange [4] - No special committee was formed for the private placement, and the Board of Directors unanimously approved the transaction [5] Group 3: Project Updates - Bessor has terminated its option to earn a 60% interest in the Easter Gold Project located in Lincoln County, Nevada [6] - The company focuses on the exploration and development of the Redhill volcanogenic massive sulphide deposit in British Columbia [7]

Core Viewpoint - Surge Copper Corp. has successfully increased its non-brokered equity financing from approximately $6.4 million to up to $10.4 million due to strong investor demand, with full subscription from both new and existing investors [1] Group 1: Offering Details - The Offering will consist of a LIFE Offering of up to 19.2 million common shares at $0.175 per share for gross proceeds of up to $3.4 million, and a LIFE Charity Flow-Through Offering of up to 9.4 million charity flow-through common shares at $0.265 per share for gross proceeds of up to $2.5 million [7] - A Concurrent Strategic Investment is expected to raise up to $4.5 million through a private placement of up to 25.8 million common shares at $0.175 per share, increasing the strategic investor's ownership to up to 19.9% [7] Group 2: Use of Proceeds - Net proceeds from the Offering will fund engineering, environmental, and early-stage permitting activities at the Berg Project, supporting the completion of a Preliminary Feasibility Study and potential entry into the Environmental Assessment process [2] - A portion of the proceeds will also be allocated for general working capital [2] Group 3: Company Overview - Surge Copper Corp. is advancing a critical metals district in British Columbia, owning a large mineral claim package with multiple advanced porphyry deposits containing copper, molybdenum, gold, and silver [9] - The Company holds a 100% interest in the Berg Project, which has a Preliminary Economic Assessment (PEA) indicating an NPV of C$2.1 billion and an IRR of 20% based on long-term commodity prices [10]

Core Viewpoint - Ensurge Micropower ASA has successfully completed a fully underwritten private placement, raising NOK 50 million through the issuance of 40 million new shares at a subscription price of NOK 1.25 per share [2]. Group 1: Private Placement Details - The private placement raised gross proceeds of NOK 50,000,000 by issuing 40,000,000 Offer Shares at a subscription price of NOK 1.25 per share [2]. - Investors in the private placement will receive one warrant for every two Offer Shares allocated, allowing them to subscribe for one new share at an exercise price of NOK 1.50 [3]. - The issuance of the warrants is subject to approval at the extraordinary general meeting expected on or about 1 August 2025 [3]. Group 2: Use of Proceeds - The net proceeds from the private placement will be utilized to accelerate the development of higher-capacity battery variants, enhance sales and marketing activities, strengthen financial flexibility, and for general corporate purposes [4]. Group 3: Underwriting and Share Capital - Certain existing shareholders have committed to fully underwrite the private placement, with an underwriting fee of 3% payable in the form of 1,200,000 new shares at the offer price [5]. - Following the completion of the private placement, the company's share capital will increase to NOK 418,390,160.50, divided into 836,780,321 shares, each with a par value of NOK 0.50 [7]. Group 4: Compliance and Market Conditions - The board has confirmed that the private placement complies with equal treatment obligations under Norwegian law and is in the common interest of the company and its shareholders [9]. - The private placement was structured to achieve a market-based subscription price, reflecting current market conditions and growth opportunities [9][10].

Core Viewpoint - Pacific Bay Minerals Ltd. announces a non-brokered private placement to raise up to $2 million to advance the Pereira-Velho Gold Project in Brazil and extends the expiry dates of certain warrants [1][2][10]. Private Placement Details - The company plans to issue up to 20,000,000 units at a price of $0.10 per unit, aiming for gross proceeds of up to $2 million [3]. - Each unit consists of one common share and one common share purchase warrant, with the warrant exercisable at $0.15 for 24 months [4]. - An acceleration clause allows the company to expedite the expiry of the warrants if the trading price exceeds $0.25 for 20 consecutive trading days [4]. Use of Proceeds - Net proceeds will primarily fund the acquisition and exploration of the Pereira-Velho Gold Project in Alagoas State, Brazil [7]. - Remaining funds may be allocated for exploration on Canadian assets and general working capital [8]. Insider Participation - Certain insiders may participate in the offering, which will be treated as a related party transaction [9]. Warrant Extension - The company intends to extend the expiry of 7,365,873 warrants issued on July 20, 2022, from July 20, 2025, to July 20, 2026, pending TSXV approval [10]. Management Update - Elton Pereira has transitioned to the role of country manager for Brazil, aligning with the company's focus on the Pereira-Velho gold project [11].

Core Viewpoint - AB Science S.A. successfully completed a private placement raising EUR 1.925 million to finance ongoing activities, particularly the clinical development of the AB8939 program [1][3]. Use of Proceeds - The net proceeds from the private placement will be utilized to support the clinical development of the AB8939 program and strengthen the company's cash position to meet financing needs for 2025 and beyond [3]. Private Placement Details - The private placement involved the issuance of 1,645,302 new ordinary shares, each with an attached share warrant (BSA), without preferential subscription rights [4][5]. - The issue price of one ABSA is EUR 1.17, reflecting a 24.36% discount to the volume-weighted average price (VWAP) of AB Science shares over the three trading days prior to the pricing [6][7]. Shareholder Impact - Post-placement, the new shares will represent approximately 2.47% of the company's share capital on a non-diluted basis before the placement and 2.41% after [5]. - Existing shareholders who do not participate in the private placement will experience a dilution of their shareholding [12][22]. Trading and Admission - The new shares are expected to be admitted to trading on Euronext Paris on July 10, 2025, and will be assimilated to existing shares [13]. Lock-up Commitments - The company has agreed to a 45-day lock-up period for the investors and a 90-day lock-up for its directors and officers following the settlement and delivery of the private placement [17].

Core Viewpoint - NorthWest Copper Corp. successfully closed an oversubscribed non-brokered private placement financing, raising a total of $555,000 through the sale of 2,775,000 units at $0.20 per unit, which will primarily be used for general working capital purposes [1][2]. Financing Details - The private placement consisted of 2,775,000 units priced at $0.20 each, resulting in gross proceeds of $555,000 [2]. - Each unit includes one common share and one half of a non-transferable common share purchase warrant, with each whole warrant exercisable at $0.30 until July 3, 2027 [2]. - The company paid cash finder's fees of $6,000 and issued 30,000 compensation warrants, also exercisable at $0.30 until July 3, 2027 [3]. Strategic Insights - CEO Paul Olmsted highlighted that the increased demand for the private placement reflects confidence in the company's new strategic approach at Kwanika, focusing on higher-grade zones within current mineralization [3]. - The financing is seen as a crucial step in preparing for the next phase of exploration drilling and metallurgical work aimed at enhancing value at Kwanika [3]. Related Party Transactions - Three directors of the company acquired a total of 400,000 units for $80,000, which qualifies as a related party transaction [5]. - These transactions are exempt from certain requirements under Multilateral Instrument 61-101 due to the fair market value of the securities not exceeding 25% of the company's market capitalization [5]. Company Overview - NorthWest Copper is engaged in copper and gold exploration and development, with a portfolio of advanced and early-stage projects in British Columbia, including Kwanika-Stardust, Lorraine-Top Cat, and East Niv [7]. - The company is positioned to benefit from a strengthening global copper market and a robust gold market, emphasizing responsible mineral exploration in collaboration with First Nations [7].

Company Overview - Actelis Networks, Inc. is a market leader in cyber-hardened, rapid deployment networking solutions for IoT and broadband applications [1][6] - The company specializes in hybrid fiber-copper networking solutions, providing fiber-grade performance with cost-efficiency [6] Private Placement Announcement - Actelis announced the closing of a private placement for the issuance and sale of 1,626,019 shares of common stock and associated warrants [1] - The purchase price for the shares and warrants was set at $0.615 per share [1][2] Financial Details - The aggregate gross proceeds from the offering were approximately $1 million, with potential additional gross proceeds of about $3 million from the warrants if fully exercised [3] - The Series A-3 warrants will expire five years from shareholder approval, while the short-term Series A-4 warrants will expire in eighteen months [2] Use of Proceeds - The company intends to use the net proceeds from the offering as working capital for general corporate purposes [3] Regulatory Information - The securities were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933 and Regulation D, and have not been registered under the Act [4]